Upstream Bio Stock Today
| UPB Stock | 29.75 2.21 8.02% |
PerformanceGood
| Odds Of DistressAverage
|
Upstream Bio is trading at 29.75 as of the 11th of January 2026, a 8.02% up since the beginning of the trading day. The stock's open price was 27.54. Upstream Bio has 53 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 12th of December 2025 and ending today, the 11th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2024 | Category Healthcare | Classification Health Care |
Upstream Bio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 54.04 M outstanding shares of which 2.98 M shares are at this time shorted by investors with about 7.89 days to cover. More on Upstream Bio
Moving together with Upstream Stock
Moving against Upstream Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Upstream Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | MD MPH | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsUpstream Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Upstream Bio's financial leverage. It provides some insight into what part of Upstream Bio's total assets is financed by creditors.
| |||||
Upstream Bio (UPB) is traded on NASDAQ Exchange in USA and employs 52 people. Upstream Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.26 B. Upstream Bio runs under Biotechnology sector within Health Care industry. The entity has 54.04 M outstanding shares of which 2.98 M shares are at this time shorted by investors with about 7.89 days to cover.
Upstream Bio generates negative cash flow from operations
Check Upstream Bio Probability Of Bankruptcy
Ownership AllocationUpstream Bio shows a total of 54.04 Million outstanding shares. The majority of Upstream Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Upstream Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Upstream Bio. Please pay attention to any change in the institutional holdings of Upstream Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly four million three hundred sixty thousand nine hundred fourteen invesors are currently shorting Upstream Bio expressing very little confidence in its future performance.
Check Upstream Ownership Details
Upstream Bio Historical Income Statement
Upstream Stock Against Markets
Upstream Bio Corporate Management
| Allison JD | General VP | Profile | |
| Aaron MD | Chief Development | Profile | |
| Adam MBA | Chief Officer | Profile | |
| Parika MS | Head Operations | Profile | |
| Maryse MS | Senior Writing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Upstream Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.